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Prime Suspect
Scientists call them the
COXs-a pair of closely-
related cyclooxygenase
enzymes that produce
prostaglandins, a class ofrela-
tively short-lived hormones that
mediate many cellular and physiolog-
ic processes. COX-1 is said to be responsi-
ble for cellular "housekeeping" functions.
COX-2 is necessary for the inflammatory
process, but can easily go astray. COX-2
has been observed at the scene and is the
prime suspect-of many a cellular "crime."
But the exact role of both enzymes is
uncertain. Pharmaceutical companies have
developed drugs to contain COX-2 at the
first sign of trouble. But scientists at the
NIEHS would like to know for sure
whether one or both enzymes are guilty of
causing damage. And they believe the best
way to determine that is by alternately
removing each enzyme from experimental
animals and observing the effects.
NSAIDs and COXs
Prostaglandins have been the subject of
considerable interest in the scientific com-
munity because of their role in inflamma-
tion. Pain and swelling occur in tissues
when cells release prostaglandins in
response to physical damage or infection,
increasing the permeability of the capillary
walls of blood vessels and attracting
immune system cells to the damaged tis-
sues. With illnesses such as rheumatoid
arthritis, however, joints can become
chronically inflamed when prostaglandins
are released in the absence of any obvious
infection or physical damage.
The recent de-
velopment of syn-
thetic nonsteroidal
antiinflammatory
drugs (NSAIDs),
such as ibuprofen,
represented a break-
through in the treat-
ment ofarthritis and
other illnesses in-
volving inflamma-
tion. NSAIDs are
believed to bring
relief by suppressing
the COX isoforms
that produce pain-
inducing prosta-
glandins. However,
the suppression of
the COXs also ne-
gates the enzymes'
beneficial role of (Ieftto right) Pat Chulad;
protecting the gas- and Burhan Ghanayem. I
tric mucosa in the digestive system.
The result has been that patients tak-
ing high dosages ofNSAIDs also suf-
fer a greatly increased incidence of
stomach ulcers.
t For manyyears, it was believed that there
was only one COX enzyme. However, in
1992, researchers discovered that corticos-
teroids, which are potent inhibitors of
inflammation, blocked the expression of a
second enzyme with COX-like activity, sub-
sequently named COX-2. COX-1 is
expressed in most tissues and mediates func-
tions including gastric cytoprotection, vascu-
lar homeostasis, and normal renal mainte-
nance. COX-2 is normally undetectable in
tissues, but can be induced at high levels in
macrophages and other cell types in response
to proinflammatory stimuli.
The presumed function of COX-2 has
sent academic and industry researchers in
hot pursuit of a drug that targets only
COX-2, while leaving COX-1 to maintain
normal homeostatic functions. At stake is a
$4 billion business that the pharmaceutical
industry has built around the
NSAID-COX connection.
COXs and Cancer
While they acknowledge the beneficial
effects of NSAIDs, NIEHS researchers
want to better understand the biological
function of the COXs in disease states.
One or both ofthe enzymes is suspected of
playing a key role in colon cancer, skin
cancer, certain kidney dysfunctions, and
failures in immune cell and reproductive
function, among other ailments. The
NIEHS has assembled a team of scientists,
the Carcinogen Metabolism and Molecular
la, Howard Tiano, Robert Langenbach, Christi
(Not pictured) Barbara Davis, Charles Loftin.
Mechanisms Group, headed by Robert
Langenbach, to conduct research aimed at
clarifying the functions of the COX
enzymes.
Langenbach's interest in the COXs
began in the early 1980s with his belief
that the one isoform known at the time
might be involved in chemically induced
bladder cancers, although he hasn't pur-
sued that particular connection. In 1991,
however, Langenbach took a sabbatical at
the University of North Carolina at
Chapel Hill's Department of Pathology,
where he learned a technique that would
allow him to pursue research on COXs. At
UNC, Langenbach worked with
researcher Oliver Smithies, who pioneered
the revolutionary technique of "knocking
out" specific genes by genetically modify-
ing the DNA ofa target gene so that it no
longer functions, putting the DNA into a
stem cell culture, and inserting the modi-
fied stem cells into a developing mice
blast. Resulting offspring that carry one
copy of the nonfunctioning gene are then
bred to produce a strain of "knockout"
mice that have no functioning copy of the
gene. "The beauty ofthis technique is that
we can have absolute inhibition of a par-
ticular gene," says Langenbach. "We can
then observe changes in the animals' phys-
iology under normal and stressed condi-
tions, and gain a clearer picture of the
gene's function."
Langenbach conducted knockout stud-
ies of the COX-1 gene, while Scott
Morham, a postdoctoral fellow in the
Smithies lab, subsequently took on the dis-
ruption of the COX-2 gene. The two
groups continue to collaborate and have
expanded the effort to include investigators
nationwide. At the NIEHS, Langenbach's
team is breeding colonies of both COX-1
and COX-2 deficient mice for use in a
variety of research projects. Biologist
Christopher Lee is responsible for main-
taining the proper breeding ofanimals and
using molecular biology techniques to
identify the COX-deficient mice to ensure
that adequate numbers of specific geno-
types are available for all studies.
"The first thing we did was to deter-
mine the physiological effects of deleting
these genes," says Langenbach.
"Preliminary findings showed high inci-
dences ofrenal failure, altered inflammato-
ry responses, and fertility difficulties in one
or both of the knockouts. These discover-
ies have opened the door to a host of pro-
jects looking at the role of the COXs in a
variety ofdiseases."
Already, certain findings have over-
turned widely held assumptions about the
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role of the COXs and NSAIDs.
Toxicologist Pat Chulada is leading an
effort to define the specific roles ofCOX-1
and COX-2 in various phases ofinflamma-
tion. Chulada's approach involves inserting
an air pouch beneath the skin of test mice
and inflating it over several days, then
injecting an irritant into the air pouch to
induce an inflammatory response that
mimics that of an arthritic joint. "The
hypothesis was that COX-2 deficient mice
would not be able to mount an inflamma-
tory response," Chulada says. "However,
our initial studies show that both COX-1
and COX-2 deficient mice do mount
inflammatory responses, although these dif-
fer from that of wild-type mice." Chaluda
is also examining how the inflammatory
process varies when subjected to various
carcinogenic and noncarcinogenic stimuli.
Toxicologist Burhan Ghanayem and
Chulada also found that, contrary to
expectations, COX-1 deficient mice did
not show an increase in stomach ulcers. In
fact, the COX-1 deficient mice were actu-
ally more resistant to NSAID-induced
stomach ulcers than the wild type. These
results indicate that NSAIDs may reduce
inflammation through mechanisms other
than or in addition to the suppression of
COXs. Further, they bring into question
the assumption that a COX-2 suppressing
drug would be a more effective antiinflam-
matory agent with less toxic side effects
than current NSAIDs. Critical findings
could come when the team compares the
health of COX knockouts with NSAID-
treated, wild-type mice.
Despite the questions they raise con-
cerning how NSAIDs work, Langenbach
sees the research as a win-win situation. "It
gives us a model to ask whether NSAIDs
have effects in addition to inhibiting the
COXs," he says. "Either they work by
inhibiting these enzymes, or they work by
alternative mechanisms. In either case, it
narrows the field in which we have to look
for answers."
Chulada is also investigating the role of
the COXs in colon cancer development.
Recent studies indicate that regular use of
NSAIDs not only reduces inflammation,
but also decreases the incidence of colon
cancer in humans by 40-50%. Scientists
have suspected that NSAIDs reduce colon
cancer by inhibiting cyclooxygenase and
decreasing the production of
prostaglandins, but the exact mechanism is
unclear. Because NSAIDs decrease the
incidence of colon cancer in rodents by as
much as 90%, Chulada is cross-breeding
COX-1 and COX-2 knockout mice that
carry a genetic mutation that predisposes
them to multiple intestinal adenomas and
monitoring the resulting hybrid mice for
onset of cancer and rates of polyp forma-
tion in the colon. These mice will also be
used to study the genetic and biochemical
changes that occur as they develop cancer.
"These studies will allow us to determine
if, in fact, NSAIDs exert their anticancer
effects by inhibiting COX-1 and COX-2
or by altering other biochemical process-
es," Chulada says. "More importantly, they
will help us to identify the mechanisms by
which each COX isozyme contributes to
colon carcinogenesis."
Molecular biologist Howard Tiano is
heading a project to examine the effect of
COX-1 and COX-2 deficiency in the
development of skin cancer in mice. The
studies being conducted will allow Tiano
and other researchers to study the role of
the COXs in both the initiation and pro-
motion stages of skin cancer. In the skin
model, as well as Chulada's colon model,
NSAIDs are being fed to wild-type and
COX-1 and COX-2 deficient mice to
determine what biochemical functions
other than COX suppression are involved
in the carcinogenesis process. "Looking at
the role of COXs in two different cancers
may give us an indication oftheir possible
involvement in a whole range of cancers,"
says Langenbach.
Future Developments
Reproductive biologist Barbara Davis is
examining how the COXs affect reproduc-
tive capabilities. COX-1 is known to have
a major role in the onset of labor, and
COX-2 is essential for ovulation. Davis is
heading a two-pronged study to determine
the effect ofgenetic deletion ofCOXgenes
on the reproductive capabilities of mice
and the effect of NSAID consumption on
these processes. The research has impor-
tant implications for whether COX-2 spe-
cific inhibitors may have unwanted side
effects and for whether pregnant women
nearing time of delivery should be taking
NSAIDs.
In addition to other studies, postdoctor-
al fellow Charles Loftin is attempting to
breed mice that are deficient in both COX-
1 and COX-2. Such doubly deficient mice,
when compared to COX-1 and COX-2
deficient mice, would provide useful models
for determining the necessity of
prostaglandins for basicbiological processes.
Langenbach anticipates that the
NIEHS research effort involving the
COXs will continue for several years,
evolving in focus and level of understand-
ing as questions are answered and new
ones posed. "The COXs are involved in
such crucial biological functions that one
line of research invariably informs anoth-
er," he says. "As we uncover the basic bio-
logical functions of COXs in normal and
stressed states, their role in specific illnesses
should become clear. And that should
allow scientists to design drugs that more
accurately prevent and treat inflammatory
diseases."
John Manuel
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